Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Oxford | OTHER |
| Imperial College London | OTHER |
| University of Dundee | OTHER |
| Mentis Cura |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a clinical study which is a follow-up of a previous prospective questionnaire study. All patients who previously participated in the study will receive a new questionnaire and will be invited for a clinical examination.
This is a clinical study which is a follow-up of a previous prospective questionnaire study. All patients who previously participated in the study will receive a new questionnaire and will be invited for a clinical examination. This is a collaboration and part of the data will be combined with other data in this collaboration
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Chemotherapy-induced Peripheral Neuropathy | For case definition of neuropathy, The Toronto classification (Tesfaye et al. 2010) will be used. Numbers indicate confirmed neuropathy. | 5-year follow-up |
| Chemotherapy-induced Neuropathic Pain | Neuropathic pain grading system. Neuropathic pain was graded as "possible", "probable", or "definite" in accordance with the NeuPSIG grading system (Pascal M et al, Wellcome Open Research 2018). | 5-year follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Sensory Abnormalities After Chemotherapy Assessed With Quantitative Sensory Testing (QST). | Modified German Research Network on Neuropathic Pain QST protocol assessed sensory abnormalities after chemotherapy assessed with quantitative sensory testing (QST). | 5-year follow-up |
| Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who underwent chemotherapy for a high-risk mamma-cancer and a high-risk colon-cancer from the period of 2011-2012 and who participated in a prospective questionnaire study (Ventzel et al. 2015).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kristine J Bennedsgaard, MD | Aarhus University Hospital and Aarhus University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Danish Pain Research Center, Aarhus University Hospital | Aarhus | 8000 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26529271 | Background | Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016 Mar;157(3):560-568. doi: 10.1097/j.pain.0000000000000404. | |
| 20876709 | Background | Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303. |
Not provided
Not provided
Data is shared among collaborators (DOLORisk consortium)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Chemotherapy | Patients treated with docetaxel or oxaliplatin. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Chemotherapy | Patients treated with docetaxel or oxaliplatin. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Chemotherapy-induced Peripheral Neuropathy | For case definition of neuropathy, The Toronto classification (Tesfaye et al. 2010) will be used. Numbers indicate confirmed neuropathy. | Posted | Number | participants | 5-year follow-up |
|
|
1 day
Adverse events only measured during survey. There is no arm or group and no intervention.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Chemotherapy | There were no adverse events | 0 |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Nanna Finnerup | Aarhus University | 0045 78463382 | finnerup@clin.au.dk |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 23, 2016 | Feb 24, 2021 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
| INDUSTRY |
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
| University of Kiel | OTHER |
| Lund University | OTHER |
| Technion, Israel Institute of Technology | OTHER |
| University Ghent | OTHER |
| Neuroscience Technologies S.L.P | INDUSTRY |
Not provided
Not provided
Not provided
Blood samples
Measurements found with threshold tracking. The most common sensory parameters assessed with sensory threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 21 for refractoriness at 2.5 ms, superexcitability and subexcitability). |
| 5-year follow-up |
| Anxiety and Depression Using the Patient Reported Outcomes Measurement Information System (PROMIS). | Number of patients with mild, moderate or severe symptoms of depression or anxiety. Patient Reported Outcomes Measurement Information System (PROMIS) used to assess if the patients has a mild, moderat or severe symptoms of depression/anxiety. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild , moderate or severe symptoms of depression or anxiety. A higher score indicates worse outcome. The minimum is no depression or anxiety and the maximum is severe depression or anxiey. Mild: T-score ≥55 and <65 Moderate: ≥65 and <75 Severe ≥75 | 5-year follow-up |
| Anxiety and Depression Using the Hospital Anxiety and Depression Scale (HADS). | Mean scores using HADS of all participants. The score for anxiety and depression indicate the sum of 7 questions, each graded from 0 to 3. This means that a person can score between 0 (minimum) and 21 (maximum) for either anxiety or depression. Higher score meaning more symptoms of a possible depression or anxiety. | 5-year follow-up |
| Fatigue Using the Patient Reported Outcomes Measurement Information System (PROMIS). | Number of patients with mild, moderate or severe fatigue. PROMIS used to assess if the patients has a mild, moderat or severe symptoms of fatique. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild, moderate or severe symptoms of fatigue. The minimum is no fatigue (T-score<50) and maximum severe fatigue (T-score ≥75). Higher scores mean a worse outcome. Mild: T-score ≥55 and <65 Moderate: ≥65 and <75 Severe ≥75 | 5-year follow-up |
| Quality of Life Using EuroQol (EQ-5D). | The participants were asked to provided a score from 1-100 regarding quality of life on the Quality of life using EuroQol (EQ-5D). Minimum score 0, maximum score 100. A higher score indicate better outcome | 5-year follow-up |
| Personality Using the 10-item Personality Inventory (TIPI). | The Personality using the 10-item Personality Inventory (TIPI). TIPI is divided in 5 parameters Extraversion, Agreeableness, Conscientiousness, Emotional Stability, Openness. Minimum value is 2 and maximum value i 14. Higher scores indicate more Openness, Conscientiousness, Extraversion, Agreeableness and Emotional Stability | 5-year follow-up |
| Personality Using the International Personality Item Pool (IPIP). | Personality using the International Personality Item Pool (IPIP). A score were given from answering 10 questions regarding emotionel stability. Each question has 5 possible answers from 1 very inaccuate to 5 very accurate. Minimum combined value 10, maximum combined value 50. Higher score indicates worse outcome. | 5-year follow-up |
| Pain Catastrophizing Using the Pain Catastrophizing Scale(PCS). | Participants answered 13 question, which were each graded on a scale from 0-4 and combined to a sum scale.. The results are a mean score for all participants. The minimum value is 0 and the maximum value is 72. Higher scores indicate more Pain catastrophizing. | 5-year follow-up |
| Morphology of Small Fibers in Cornea After Chemotherapy by Corneal Confocal Microscopy (CCM). | The fibers in the cornea were scanned in one eye with the Heidelberg Retina Tomograph III laser-scanning confocal microscope (Heidelberg Engineering GmbH, Heidelberg, Germany). An automatic programme calculated the cornea nerve branches density (CNBD) and the cornea nerve fiber density (CNFD). | 5-year follow-up |
| Blood Samples DNA | Numbers indicate the number of participants, who had a blood sample collected. Potential gene associations in the development of painful neuropathy will be assessed together with other samples in the DOLORisk collaboration. The results here present the number of subjects who had a DNA blood sample taken. | 5-year follow-up |
| Pain Interference by Patient Reported Outcomes Measurement Information System (PROMIS). | Numbers given is patients with mild, moderate or severe pain interference of the patients with neuropathic pain. Patient Reported Outcomes Measurement Information System PROMIS used to assess if the patients has a mild, moderate or severe symptoms of pain interference. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild, moderate or severe pain interference. The mimimum is no interference (T-score <50) and maximum is Severe (T-score≥70)). Severe indicated more interference | 5-year follow-up |
| Pain Descriptors by Douleur Neuropathique 4 (DN4). | number of participants with a possible painful neuropathy with the Douleur Neuropathique 4DN4. Yes/no questions regarding symptoms and signs of neuropathic pain. In total the participants answered 7 questions. Each question is a yes or no and are combined to a sum score of number of positive answers. Minimum score is 0 and maximum score is 7. Higher score indicates larger probability of neuropathic Pain. A score of 3 or above indicates a possible painful neuropathy. | 5-Year follow-up |
| Pain Descriptors by Neuropathic Pain Symptom Inventory (NPSI). | The results were given on a scale from 0-100 for each of the 5 dimensions on the Neuropathic Pain Symptom Inventory (NPSI). Higher scores indicate worse symptoms. The sum score is the sum divided by 5. Minimum score is 0 and maximum score is 100. | 5-Year follow-up |
| Neuropathy Using the Toronto Clinical Scoring System (TCSS). | The Toronto Clinical Scoring System(TCSS), grades the severity of neuropathy and consists of 6 questions with the presence and description of symptoms and a 7-item clinical examination with reflexes in the lower extremities and a bedside sensory testing with pinprick, vibration, temperature, light touch and position of the 1st toe. The score ranges from 0-19. Higher score indicate worse outcome. | 5-year follow-up |
| Neuropathy Using the Total Neuropathy Score. | The TNScompact consists of 7 questions regarding sensory symptoms, motor symptoms, autonomic symptoms, pin sensation, vibrations sensitivity, strength and tendon reflexes graded from 0-4. The scores are combined and thus 0 being the lowest score possible and 28 being the highest score possible. A high score indicate severe neuropathy. | 5-year follow-up |
| Neuropathy Using the Michigan Neuropathy Screening Instrument (MNSI). | A cut-off ≥ 4/13 abnormal responses has been suggested as the cut-off to define polyneuropathy. | 5-year follow-up |
| Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor | Measurements found with threshold tracking. The most common motor parameters assessed with threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 22 for refractoriness at 2.5 ms, superexcitability and subexcitability). | 5-year follow-up |
| Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory | Measurements found with threshold tracking. The most common sensory parameters assessed with sensory threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 21 for refractoriness at 2.5 ms, superexcitability and subexcitability). Superexcitability and subexcitablity are measured in the recovery period. The recovery cycle is characterized by changes in axonal excitability following a supramaximal conditioning stimulus. The cycle includes a relative refractory period (at short inter-stimulus intervals), superexcitable period (when the threshold is reduced), and subexcitable period (when the nerve is less excitable). | 5-year follow-up |
| Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor | Measurements found with threshold tracking. The most common motor parameters assessed with threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten (RRP) makes the nerve more excitable and longer RRP less excitable (values see result 22 for refractoriness at 2.5 ms, superexcitability and subexcitability). Superexcitability and subexcitablity are measured in the recovery period. The recovery cycle is characterized by changes in axonal excitability following a supramaximal conditioning stimulus. The cycle includes a relative refractory period (at short inter-stimulus intervals), superexcitable period (when the threshold is reduced), and subexcitable period (when the nerve is less excitable). | 5-year follow-up |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
| Primary | Chemotherapy-induced Neuropathic Pain | Neuropathic pain grading system. Neuropathic pain was graded as "possible", "probable", or "definite" in accordance with the NeuPSIG grading system (Pascal M et al, Wellcome Open Research 2018). | Posted | Count of Participants | Participants | 5-year follow-up |
|
|
|
| Secondary | Sensory Abnormalities After Chemotherapy Assessed With Quantitative Sensory Testing (QST). | Modified German Research Network on Neuropathic Pain QST protocol assessed sensory abnormalities after chemotherapy assessed with quantitative sensory testing (QST). | Patients with an abnormal value indicating loss of function | Posted | Number | participants | 5-year follow-up |
|
|
|
| Secondary | Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory | Measurements found with threshold tracking. The most common sensory parameters assessed with sensory threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 21 for refractoriness at 2.5 ms, superexcitability and subexcitability). | Sensory recordings from participants, the relative refractory period | Posted | Mean | Standard Error | ms | 5-year follow-up |
|
|
|
| Secondary | Anxiety and Depression Using the Patient Reported Outcomes Measurement Information System (PROMIS). | Number of patients with mild, moderate or severe symptoms of depression or anxiety. Patient Reported Outcomes Measurement Information System (PROMIS) used to assess if the patients has a mild, moderat or severe symptoms of depression/anxiety. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild , moderate or severe symptoms of depression or anxiety. A higher score indicates worse outcome. The minimum is no depression or anxiety and the maximum is severe depression or anxiey. Mild: T-score ≥55 and <65 Moderate: ≥65 and <75 Severe ≥75 | Posted | Number | participants | 5-year follow-up |
|
|
|
| Secondary | Anxiety and Depression Using the Hospital Anxiety and Depression Scale (HADS). | Mean scores using HADS of all participants. The score for anxiety and depression indicate the sum of 7 questions, each graded from 0 to 3. This means that a person can score between 0 (minimum) and 21 (maximum) for either anxiety or depression. Higher score meaning more symptoms of a possible depression or anxiety. | Posted | Mean | Standard Deviation | score on a scale | 5-year follow-up |
|
|
|
| Secondary | Fatigue Using the Patient Reported Outcomes Measurement Information System (PROMIS). | Number of patients with mild, moderate or severe fatigue. PROMIS used to assess if the patients has a mild, moderat or severe symptoms of fatique. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild, moderate or severe symptoms of fatigue. The minimum is no fatigue (T-score<50) and maximum severe fatigue (T-score ≥75). Higher scores mean a worse outcome. Mild: T-score ≥55 and <65 Moderate: ≥65 and <75 Severe ≥75 | Numbers given is patients with mild, moderate or severe fatigue. | Posted | Count of Participants | Participants | 5-year follow-up |
|
|
|
| Secondary | Quality of Life Using EuroQol (EQ-5D). | The participants were asked to provided a score from 1-100 regarding quality of life on the Quality of life using EuroQol (EQ-5D). Minimum score 0, maximum score 100. A higher score indicate better outcome | Posted | Mean | Standard Deviation | units on a scale | 5-year follow-up |
|
|
|
| Secondary | Personality Using the 10-item Personality Inventory (TIPI). | The Personality using the 10-item Personality Inventory (TIPI). TIPI is divided in 5 parameters Extraversion, Agreeableness, Conscientiousness, Emotional Stability, Openness. Minimum value is 2 and maximum value i 14. Higher scores indicate more Openness, Conscientiousness, Extraversion, Agreeableness and Emotional Stability | Answers are missing for 1 participant. | Posted | Mean | Standard Deviation | units on a scale | 5-year follow-up |
|
|
|
| Secondary | Personality Using the International Personality Item Pool (IPIP). | Personality using the International Personality Item Pool (IPIP). A score were given from answering 10 questions regarding emotionel stability. Each question has 5 possible answers from 1 very inaccuate to 5 very accurate. Minimum combined value 10, maximum combined value 50. Higher score indicates worse outcome. | Results from 1 participant were missing | Posted | Mean | Standard Deviation | score on a scale | 5-year follow-up |
|
|
|
| Secondary | Pain Catastrophizing Using the Pain Catastrophizing Scale(PCS). | Participants answered 13 question, which were each graded on a scale from 0-4 and combined to a sum scale.. The results are a mean score for all participants. The minimum value is 0 and the maximum value is 72. Higher scores indicate more Pain catastrophizing. | Posted | Mean | Standard Deviation | score on a scale | 5-year follow-up |
|
|
|
| Secondary | Morphology of Small Fibers in Cornea After Chemotherapy by Corneal Confocal Microscopy (CCM). | The fibers in the cornea were scanned in one eye with the Heidelberg Retina Tomograph III laser-scanning confocal microscope (Heidelberg Engineering GmbH, Heidelberg, Germany). An automatic programme calculated the cornea nerve branches density (CNBD) and the cornea nerve fiber density (CNFD). | Missing data in 10 patients | Posted | Mean | Standard Deviation | units/mm2 | 5-year follow-up |
|
|
|
| Secondary | Blood Samples DNA | Numbers indicate the number of participants, who had a blood sample collected. Potential gene associations in the development of painful neuropathy will be assessed together with other samples in the DOLORisk collaboration. The results here present the number of subjects who had a DNA blood sample taken. | Numbers indicate the number of participants, who had a blood sample collected. Not analyzed separately | Posted | Number | participants | 5-year follow-up |
|
|
|
| Secondary | Pain Interference by Patient Reported Outcomes Measurement Information System (PROMIS). | Numbers given is patients with mild, moderate or severe pain interference of the patients with neuropathic pain. Patient Reported Outcomes Measurement Information System PROMIS used to assess if the patients has a mild, moderate or severe symptoms of pain interference. The scores from the questionnaires were converted into T-scores, which were used in grading the patients with mild, moderate or severe pain interference. The mimimum is no interference (T-score <50) and maximum is Severe (T-score≥70)). Severe indicated more interference | Of the 63 included in the study, 19 patients had symptoms of neuropathic pain. Numbers given is patients with mild, moderate or severe pain interference of the patients with neuropathic pain. | Posted | Count of Participants | Participants | 5-year follow-up |
|
|
|
| Secondary | Pain Descriptors by Douleur Neuropathique 4 (DN4). | number of participants with a possible painful neuropathy with the Douleur Neuropathique 4DN4. Yes/no questions regarding symptoms and signs of neuropathic pain. In total the participants answered 7 questions. Each question is a yes or no and are combined to a sum score of number of positive answers. Minimum score is 0 and maximum score is 7. Higher score indicates larger probability of neuropathic Pain. A score of 3 or above indicates a possible painful neuropathy. | Of the 63 included in the study, 19 patients had symptoms of neuropathic pain. The result are the number of participants with a possible painful neuropathy with the DN4. | Posted | Count of Participants | Participants | 5-Year follow-up |
|
|
|
| Secondary | Pain Descriptors by Neuropathic Pain Symptom Inventory (NPSI). | The results were given on a scale from 0-100 for each of the 5 dimensions on the Neuropathic Pain Symptom Inventory (NPSI). Higher scores indicate worse symptoms. The sum score is the sum divided by 5. Minimum score is 0 and maximum score is 100. | Of the 63 included in the study, 19 patients had symptoms of neuropathic pain. The result are the score of participants with a neuropathic pain. | Posted | Mean | Standard Deviation | score on a scale | 5-Year follow-up |
|
|
|
| Secondary | Neuropathy Using the Toronto Clinical Scoring System (TCSS). | The Toronto Clinical Scoring System(TCSS), grades the severity of neuropathy and consists of 6 questions with the presence and description of symptoms and a 7-item clinical examination with reflexes in the lower extremities and a bedside sensory testing with pinprick, vibration, temperature, light touch and position of the 1st toe. The score ranges from 0-19. Higher score indicate worse outcome. | Results wer missing in 4 participants. | Posted | Mean | Standard Deviation | score on a scale | 5-year follow-up |
|
|
|
| Secondary | Neuropathy Using the Total Neuropathy Score. | The TNScompact consists of 7 questions regarding sensory symptoms, motor symptoms, autonomic symptoms, pin sensation, vibrations sensitivity, strength and tendon reflexes graded from 0-4. The scores are combined and thus 0 being the lowest score possible and 28 being the highest score possible. A high score indicate severe neuropathy. | The results were missing for 5 participants. | Posted | Mean | Standard Deviation | score on a scale | 5-year follow-up |
|
|
|
| Secondary | Neuropathy Using the Michigan Neuropathy Screening Instrument (MNSI). | A cut-off ≥ 4/13 abnormal responses has been suggested as the cut-off to define polyneuropathy. | Posted | Count of Participants | Participants | 5-year follow-up |
|
|
|
| Secondary | Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor | Measurements found with threshold tracking. The most common motor parameters assessed with threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 22 for refractoriness at 2.5 ms, superexcitability and subexcitability). | Motor recordings from participants, relative refractory period | Posted | Mean | Standard Error | ms | 5-year follow-up |
|
|
|
| Secondary | Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory | Measurements found with threshold tracking. The most common sensory parameters assessed with sensory threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten RRP makes the nerve more excitable and longer RRP less excitable (values see result 21 for refractoriness at 2.5 ms, superexcitability and subexcitability). Superexcitability and subexcitablity are measured in the recovery period. The recovery cycle is characterized by changes in axonal excitability following a supramaximal conditioning stimulus. The cycle includes a relative refractory period (at short inter-stimulus intervals), superexcitable period (when the threshold is reduced), and subexcitable period (when the nerve is less excitable). | Sensory recordings from participants, refractoriness at 2.5 ms, superexcitability and subexcitability | Posted | Mean | Standard Error | percentage of 100% | 5-year follow-up |
|
|
|
| Secondary | Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor | Measurements found with threshold tracking. The most common motor parameters assessed with threshold tracking. Outcomes are extracted from the QTrack software. The relative refractory period (RRP) is the interval of time during which a second action potential can be initiated, refractoriness is change in threshold by a preceding simple impulse, and specifically at 2,5 ms. A shorten (RRP) makes the nerve more excitable and longer RRP less excitable (values see result 22 for refractoriness at 2.5 ms, superexcitability and subexcitability). Superexcitability and subexcitablity are measured in the recovery period. The recovery cycle is characterized by changes in axonal excitability following a supramaximal conditioning stimulus. The cycle includes a relative refractory period (at short inter-stimulus intervals), superexcitable period (when the threshold is reduced), and subexcitable period (when the nerve is less excitable). | Motor recordings from participants, refractoriness at 2.5 ms, superexcitability and subexcitability | Posted | Mean | Standard Error | percentage of 100% | 5-year follow-up |
|
|
|
| 63 |
| 0 |
| 63 |
| 0 |
| 63 |
Not provided
Not provided
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Title | Measurements |
|---|---|
|
| Abnormal paradoxical heat sensation |
|
| Abnormal mechanical pain threshold |
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Emotional Stability |
|
| Openness |
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|